FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Chronic Kidney Disease | Empagliflozin | Grants | Jardiance | Research | Urology & Nephrology